On- and off-target gene editing assessment services
Patient safety is critical for regulatory success. SeQure Dx specializes in off-target analysis services to reduce risk and improve the safety profile of gene-edited cell and gene therapies. Our advanced assays ensure precise editing confirmation and thorough risk assessment across viral and non-viral editing platforms. By addressing potential risks early, we help developers make data-driven decisions, reduce costs, and create safer, more effective therapies—accelerating their path to patients.
Comprehensive suite of assays from discovery to IND
Understanding the off-target editing profile of cell and gene therapy programs earlier in the discovery process increases the likelihood of success and decreases the risk of significant unexpected costs, delays and program halts. SeQure Dx offers Screening, Nomination and Confirmation assays to speed your way to the clinic with safer therapies.
J. Keith Joung, MD, PhD
Scientific Founder
History of Secure Dx
SeQure Dx began with a mission to reduce the risk of cell therapy development and manufacturing, ensuring safer therapies reach patients faster. By creating leading on-target and off-target assessment assays, we empower precision medicine advancements and remain committed to transforming the future of healthcare.
The SeQure Dx assay portfolio aligns with most recent FDA guidance for gene edited therapies.
Featured Resources
Have questions?
